Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 609 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Zolbetuximab August 28, 2024 Experimental Cancer Drug Metarrestin Targets Metastatic Tumors May 29, 2018 How a Musician Copes With Life With Metastatic Breast Cancer March 17, 2021 Nanoparticle Trains Immune Cells to Attack Cancer December 4, 2020 Load more HOT NEWS Living with a stoma: Neil and Lindsay share their experiences after... FDA Approves Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma FDA Approves Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma ΝΕΑ ΓΙΑ ΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ
